[[Gastric mucosa]] typically is composed of salts and other dialyzable components, free proteins, carbohydrate rich glycoprotein and water. Troxipide fortifies this [[gastric mucosal barrier]] by increasing the content of [[glucosamine]], [[mucopolysaccharides]] and [[collagen]].<ref name="pmid6489865">{{cite journal |vauthors=Abe Y, Sekiguchi H, Tsuru K, Irikura T |title=Effects of 3,4,5-trimethoxy-N-(3-piperidyl) benzamide (KU-54) on the incorporation (excretion) of <sup>14</sup>C-glucosamine in the gastric mucosa and the liver of rats (Article in Japanese) |journal=Nihon Yakurigaku Zasshi |year=1984 |volume=84 |issue=1 |pages=11–8 |pmid=6489865}}</ref><ref name="Trox1">Prescribing information of APLACE (Troxipide). 2008. Kyorin Pharmaceutical Co., Ltd., Japan [http://www.kegg.jp/medicus-bin/japic_med?japic_code=00054626]</ref> Glucosamine is an amino-sugar that is known to stimulate glycoprotein synthesis and protective mechanisms of the gastric mucosa, thereby aiding in ulcer healing.<ref name="pmid17504261">{{cite journal |vauthors=Santhosh S, Anandan R, Sini TK, Mathew PT |title=Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats |journal=J Gastroenterol Hepatol |year=2007 |volume=22 |issue=6 |pages=949–53 |pmid=17504261 |doi=10.1111/j.1440-1746.2007.04840.x}}</ref> Mucopolysaccharides impart structural integrity to the gastric mucosa and collagen imparts properties like ionic capability to attract blood components essential to tissue regeneration, mechanical protection, high tensile strength and slow digestibility to the gastric mucosa.<ref name="pmid6651769">{{cite journal |vauthors=Clamp JR, Cooper B, Creeth JM, Ene D, Barrett J, Gough M |title=The presence of polysaccharide in normal human gastric mucus |journal=Biochem J |year=1983 |volume=215 |issue=2 |pages=421–3 |pmid=6651769 |pmc=1152412}}</ref><ref name="pmid17472480">{{cite journal |vauthors=Castro GA, Sgarbieri VC, Carvalho JE, Tinti SV, Possenti A |title=Protective effect of collagen derivates on the ulcerative lesions caused by oral administration of ethanol |journal=J Med Food |year=2007 |volume=10 |issue=1 |pages=154–8 |pmid=17472480 |doi=10.1089/jmf.2006.262}}</ref>

 
Almost all of the gastric mucosal defense mechanisms are stimulated and/or facilitated by [[prostaglandins]] (PGs), especially [[prostaglandin E2|PGE<sub>2</sub>]].<ref name="pmid18549814">{{cite journal |vauthors=Laine L, Takeuchi K, Tarnawski A |title=Gastric mucosal defense and cytoprotection: bench to bedside |journal=Gastroenterology |volume=135 |issue=1 |pages=41–60 |pmid=18549814 |doi=10.1053/j.gastro.2008.05.030}}</ref> These cytoprotective PGs stimulate mucus, bicarbonate, and phospholipid secretion; increase mucosal blood flow; and accelerate epithelial [[Gastric mucosal restitution|restitution and mucosal healing]]. They also inhibit [[mast cell]] activation, and [[leukocyte]] and [[platelet]] adherence to the vascular endothelium. Thus, continuous generation of PGE<sub>2</sub> by gastric mucosa is crucial for the maintenance of mucosal integrity and protection against ulcerogenic and necrotizing agents.<ref name="pmid18549814" /> Troxipide is known to stimulate the release of PGE<sub>2</sub> and [[prostaglandin D2|PGD<sub>2</sub>]] in experimental as well as clinical studies. Troxipide has been observed to enhance PG-stimulated increase in gastric mucosal output, accelerated epithelial restitution and mucosal healing.<ref name="current1">{{cite journal |vauthors=Mine T, Kataoka A, Fujisaki J |title=Effects of cimetidine and troxipide on gastric mucosal prostaglandin synthesis in patients with chronic gastric ulcer |journal=Curr Ther Res |volume=50 |issue=6 |pages=878–87}}</ref>

 
In addition to inhibition of pro-inflammatory mediators, troxipide directly acts on the enzymes such as xanthine oxidase and myeloperoxidase that generate free oxygen radicals in gastric mucosa.<ref name="pmid7959422">{{cite journal |vauthors=Momo K, Hoshina K, Ishibashi Y, Saito T |title=Preventive effects of troxipide on a newly developed model of acute gastric mucosal lesion (AGML) induced by ischemia/reperfusion plus ammonia in the rat (Article in Japanese) |journal=Nihon Yakurigaku Zasshi |year=1994 |volume=104 |issue=4 |pages=313–23 |pmid=7959422 |doi=10.1254/fpj.104.313}}</ref> Experimental studies have demonstrated that troxipide restrains [[NSAID]]-induced generation of porphyrins, tissue peroxidation and gastric lesion formation.<ref name="pmid11281183">{{cite journal |vauthors=Matsui H, Murata Y, Kobayashi F, Shiba R, Momo K, Kondo Y, Nakahara A, Muto H |title=Diclofenac-induced gastric mucosal fluorescence in rats |journal=Dig Dis Sci |year=2001 |volume=46 |issue=2 |pages=338–44 |pmid=11281183 |doi=10.1023/A:1005656916830}}</ref>

 
Gastric [[parietal cell]]s are rich in mitochondria which provide energy in the form of [[Adenosine triphosphate|ATP]] for cells by oxidative phosphorylation, critical to maintain the proper morphology and function of gastric mucosa. The mitochondrion is the major target of intracellular oxidative stress associated with aggressive factors like ''[[H. pylori]]'', alcohol and [[NSAID]]s,<ref name="pmid18855985">{{cite journal |vauthors=Pan JS, He SZ, Xu HZ, Zhan XJ, Yang XN, Xiao HM, Shi HX, Ren JL |title=Oxidative stress disturbs energy metabolism of mitochondria in ethanol-induced gastric mucosa injury |journal=World J Gastroenterol |year=2008 |volume=14 |issue=38 |pages=5857–67 |pmid=18855985 |doi=10.3748/wjg.14.5857 |pmc=2751896}}</ref> which disturb the energy metabolism of mitochondria. Troxipide accelerates oxygen intake of marginal gastric mucosa and glycogen consumptive stimulation of the gastric mucosa of the corpus,<ref name="pmid6745811">{{cite journal |vauthors=Abe Y, Sekiguchi H, Tsuru K, Irikura T |title=Effects of 3,4,5-trimethoxy-N-(3-piperidyl) benzamide (KU-54) on respiration of the gastric mucosa and liver in rats (Article in Japanese) |journal=Nihon Yakurigaku Zasshi |year=1984 |volume=83 |issue=4 |pages=317–24 |pmid=6745811 |doi=10.1254/fpj.83.317}}</ref> thereby elevating the tissue respiration and energy metabolism.

 
Troxipide is well absorbed throughout the gastrointestinal tract with a relative bioavailability of 99.6%.<ref name = "Zhao_2003">{{cite journal |vauthors=Zhao Y, Qiu R, Wang W, Sun H, Dai M, Yang Q, Mao G |date=June 2003 | title = Relative bioavailability and bioequivalance of troxipide capsule in healthy volunteers after a single oral administration | journal = The Chinese Journal of Clinical Pharmacology | volume = | issue = | pages =  | url = http://en.cnki.com.cn/Article_en/CJFDTOTAL-GLYZ200306013.htm  }}</ref> At any time, a mean concentration of 5.3- 8.9&nbsp;µg of troxipide is present per gram of tissue, which is capable of inhibiting the chemotactic migration and superoxide generation in the gastric mucosa. Thus, even 3 hrs after attaining peak serum levels, troxipide is found in therapeutically active concentrations in the small intestine, liver and stomach.<ref name="pmid11515628">{{cite journal |vauthors=Kusugami K, Ina K, Hosokawa T, Kobayashi F, Kusajima H, Momo K, Nishio Y | title = Troxipide, a novel antiulcer compound, has inhibitory effects on human neutrophil migration and activation induced by various stimulants | journal = Dig Liver Dis | volume = 32 | issue = 4 | pages = 305–11 |date=May 2000 | pmid = 11515628 | doi = 10.1016/S1590-8658(00)80023-7}}</ref> The elimination half-life of troxipide is 7.5 hours, and is mainly excreted in urine (96% as metabolites).<ref name="Trox1" />
